Filtered By:
Condition: Atrial Fibrillation
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 444 results found since Jan 2013.

The noninferiority of transcatheter aortic valve implantation compared to surgical aortic valve replacement for severe aortic disease: Evidence based on 16 randomized controlled trials
Conclusions: Our analysis shows that TAVI was equal to sAVR in early, midterm and long term mortality for patients with severe aortic disease. In addition, TAVI may be favorable in reducing the incidence of both early, midterm and long term NOAF. However, pooled results showed superiority of sAVR in reducing permanent pacemaker implantation, neurological events, TIA, major vascular complications and reintervention.
Source: Medicine - July 16, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Comparison of postprocedural new-onset atrial fibrillation between transcatheter and surgical aortic valve replacement: A systematic review and meta-analysis based on 16 randomized controlled trials
Conclusions: Our analysis showed that TAVR was superior to SAVR in decreasing the both short and long term postprocedural NOAF. TAVR was equal to SAVR in early, midterm and long term mortality. In addition, TAVR showed lower incidence of 30-day/in-hospital MI and cardiogenic shock after procedure. However, pooled results showed that TAVR was inferior to SAVR in reducing permanent pacemaker implantation, neurological events, TIA, major vascular complications, and re-intervention.
Source: Medicine - July 16, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoaugulant: A case report
Rationale: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity, especially stroke and heart failure. There is also increasing awareness that atrial fibrillation is a major cause of embolic events which in 75% of cases are complicated by cerebrovascular accidents. Patient concerns: A 50-year-old woman with mitral bioprosthesis under warfarin for nonvalvular atrial fibrillation was referred to our Coronary Intensive Care Unit due to acute myocardial infarction without evidence of significant coronary artery stenosis. Diagnoses: Cardiovascular examination...
Source: Medicine - June 11, 2021 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Commentary: Direct oral anticoagulants in heart surgery: A  question in need of an answer
The Invited Expert Opinion by Drs Kapadia and Svensson1 is focused on an important clinical challenge of whether direct oral anticoagulants (DOACs) can be used in patients with bioprosthetic valves who have atrial fibrillation (AF). Recommendations for anticoagulation therapy should focus on potential risks of early postoperative bleeding with DOAC treatment and not only on its long-term superiority over vitamin K antagonists (VKAs) for stroke prevention in patients with AF, with or without a bioprosthetic valve.
Source: The Journal of Thoracic and Cardiovascular Surgery - June 10, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Stephen D. Waterford, Niv Ad Tags: Commentary Source Type: research

Commentary: Direct oral anticoagulants in heart surgery: A  question in need of an answer
The Invited Expert Opinion by Drs Kapadia and Svensson1 is focused on an important clinical challenge of whether direct oral anticoagulants (DOACs) can be used in patients with bioprosthetic valves who have atrial fibrillation (AF). Recommendations for anticoagulation therapy should focus on potential risks of early postoperative bleeding with DOAC treatment and not only on its long-term superiority over vitamin K antagonists (VKAs) for stroke prevention in patients with AF, with or without a bioprosthetic valve.
Source: The Journal of Thoracic and Cardiovascular Surgery - June 10, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Stephen D. Waterford, Niv Ad Tags: Commentary Source Type: research

Evaluation of Prescribing Practices and Outcomes Using Direct-Acting Oral Anticoagulants After Cardiac Surgery
Clin Ther. 2021 May 30:S0149-2918(21)00203-4. doi: 10.1016/j.clinthera.2021.04.009. Online ahead of print.ABSTRACTPURPOSE: Cardiac surgery patients frequently require anticoagulation. Warfarin remains the preferred agent, and a few trials have reported negative outcomes with the use of direct-acting oral anticoagulants (DOACs) in these patients. Therefore, limited literature exists that supports the dosing, safety, and efficacy of DOACs within the cardiac surgery population.METHODS: This single-center, retrospective analysis was conducted at a tertiary academic medical center. All data were extrapolated from electronic med...
Source: Clinical Therapeutics - June 3, 2021 Category: Drugs & Pharmacology Authors: Dareen M Kanaan Bryan M Cook Julie Kelly Rhynn Malloy Source Type: research

Balloon Aortic Valvuloplasty With Same-Setting Complex Percutaneous Coronary Intervention in the TAVR Era: A Case Series
CONCLUSIONS: BAV with same-setting complex PCI is safe and feasible in patients with severe AS and severe CAD awaiting TAVR.PMID:34077385
Source: The Journal of Invasive Cardiology - June 2, 2021 Category: Cardiology Authors: Puja B Parikh Samantha Weber-Fishkin Sareena George Jesse Kane Robert Pyo Source Type: research

Direct comparison of rapid deployment versus sutureless aortic valve replacement: a meta-analysis
CONCLUSIONS: AVR using RD valve was associated with better valve hemodynamics in terms of the MPG than AVR using SU valve, and better outcomes were observed in the RD group regarding PPI. Procedural times were longer in AVR using RD valve than SU valve. Early clinical outcomes showed no difference between RD and SU valve.PMID:34012571 | PMC:PMC8107528 | DOI:10.21037/jtd-20-3548
Source: Journal of Thoracic Disease - May 20, 2021 Category: Respiratory Medicine Authors: Suk Ho Sohn Yoonjin Kang Ji Seong Kim Jae Woong Choi Myoung-Jin Jang Ho Young Hwang Source Type: research